The importance of developing therapies targeting the biological spectrum of metastatic disease

Tools

Item Type:	Editorial
Title:	The importance of developing therapies targeting the biological spectrum of metastatic disease
Creators Name:	Zijlstra, A., Von Lersner, A., Yu, D., Borrello, L., Oudin, M., Kang, Y., Sahai, E., Fingleton, B., Stein, U., Cox, T.R., Price, J.T., Kato, Y., Welm, A.L. and Aguirre-Ghiso, J.A.
Abstract:	Great progress has been made in cancer therapeutics. However, metastasis remains the predominant cause of death from cancer. Importantly, metastasis can manifest many years after initial treatment of the primary cancer. This is because cancer cells can remain dormant before forming symptomatic metastasis. An important question is whether metastasis research should focus on the early treatment of metastases, before they are clinically evident ("overt"), or on developing treatments to stop overt metastasis (stage IV cancer). In this commentary we want to clarify why it is important that all avenues of treatment for stage IV patients are developed. Indeed, future treatments are expected to go beyond the mere shrinkage of overt metastases and will include strategies that prevent disseminated tumor cells from emerging from dormancy.
Keywords:	Stage IV Cancer, Minimal Residual Disease, Metastasis, Cancer Dormancy, Liquid Biopsy, Animals
Source:	Clinical and Experimental Metastasis
ISSN:	0262-0898
Publisher:	Springer
Volume:	36
Number:	4
Page Range:	305-309
Date:	August 2019
Additional Information:	Copyright © Springer Nature B.V. 2019
Official Publication:	https://doi.org/10.1007/s10585-019-09972-3
External Fulltext:	View full text on PubMed Central
PubMed:	View item in PubMed

Repository Staff Only: item control page